Physician profile
Toufic Kachaamy
NPI 1831174549
$210,062.69
in general payments reported to CMS, 2019-2025
32 companies · $72K in 2025
The $72K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,914 · 2020: $223 · 2021: $611 · 2022: $23K · 2023: $33K · 2024: $77K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $125K · Travel and Lodging: $44K · Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $124,760.58 |
| Travel and Lodging | $43,939.96 |
| Food and Beverage | $10,295.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Endoscopy | $61,206.33 | 2022-2025 | |
| Olympus Corporation | $48,043.42 | 2024-2025 | Evis Exera III Colonovideoscope |
| Micro-Tech Endoscopy USA, INC. | $24,576.85 | 2022-2025 | Eus Needles, Eyemax |
| Olympus Corporation of The Americas | $19,991.26 | 2023-2025 | Evis Exera III Colonovideoscope, Evis Exera Lll Colonovideoscope, Gyrus Acmi, INC |
| Steris Corporation | $16,154.02 | 2021-2025 | |
| Pentax of America, INC. | $13,545.99 | 2022-2025 | Pentax Medical, C2 Cryoballoon, Inspira |
| Medtronic, INC. | $6,884.60 | 2021-2025 | Gi Genius, Endoflip, Prodigi |
| Cook Incorporated | $5,085.00 | 2025 | Echotip Insight |
| Boston Scientific Corporation | $3,591.78 | 2019-2024 | Orise, Spyglass, Spyglass |
| Olympus Medical Systems Corporation | $3,462.50 | 2024-2025 | Evis Exera III Duodenovideoscope |
| Csa Medical, INC | $2,766.66 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $937.63 | 2025 | |
| Cook Medical LLC | $761.48 | 2022-2025 | Echotip Insight, Echotip |
| Omega Medical Imaging, LLC | $691.49 | 2019 | |
| Olympus America INC. | $458.80 | 2022-2025 | Evis Exera III Video System Center, Evis Exera III Bronchovideoscope, Evis X1 Video System Center |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $256.72 | 2024-2025 | |
| Digestive Care, INC. | $210.52 | 2025 | Pertzye |
| 3-D Matrix, INC. | $175.55 | 2025 | |
| Galvanize Therapeutics, INC | $163.12 | 2023-2024 | Aliya System |
| Exact Sciences Corporation | $158.47 | 2023 | |
| Celgene Corporation | $140.00 | 2019 | |
| Genentech USA, INC. | $136.35 | 2020 | |
| Gilead Sciences, INC. | $120.81 | 2024 | Livdelzi |
| Lucid Diagnostics INC. | $116.44 | 2021 | |
| Lilly USA, LLC | $105.32 | 2019 | |
| Covidien Lp | $86.85 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.29 | 2025 | |
| Creo Medical INC. | $48.65 | 2024 | Speedboat Ultraslim (Sb1l) |
| Ipsen Biopharmaceuticals, INC | $47.90 | 2025 | Onivyde |
| Pinnacle Biologics, INC | $21.08 | 2019 | |
| Ambu INC. | $20.81 | 2021 | |
| W. L. Gore & Associates, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toufic Kachaamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.